A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.
Sacco JJ, Jackson R, Corrie P, Danson S, Evans TRJ, Ochsenreither S, Kumar S, Goodman A, Larkin J, Karydis I, Steven N, Lorigan P, Plummer R, Patel P, Psarelli E, Olsson-Brown A, Shaw H, Leyvraz S, Handley L, Rawcliffe C, Nathan P.
Sacco JJ, et al. Among authors: goodman a.
Eur J Cancer. 2024 Mar 11;202:114009. doi: 10.1016/j.ejca.2024.114009. Online ahead of print.
Eur J Cancer. 2024.
PMID: 38547774
Free article.